Key result
Acute ischemic stroke thrombolysis expands via increased tenecteplase adoption and broader indications alongside thrombectomy.
Why the study?
Substantial changes have been made in the use of intravenous thrombolysis for acute ischemic stroke over the past 5 years, with integrating IVT and endovascular thrombectomy representing a particular challenge.
Answers are grounded in this paper and cite their sources.
May guide updates to stroke care pathways; leaves open need for trials on optimal tenecteplase use with thrombectomy.
In the past 5 years, substantial changes have been made in the use of intravenous thrombolysis (IVT) in patients with acute ischemic stroke. Integrating IVT with endovascular thrombectomy, which improves outcomes in patients with stroke due to large cerebral vessel occlusion, has been a particular challenge. This review discusses the underlying vascular targets for IVT and thrombectomy, the increasing use of tenecteplase instead of alteplase, broadening indications for the use of IVT, and ancillary drugs and dosing methods that may augment the success of IVT.
No takes yet. Share an insight, caveat, or question.
James C. Grotta (2026) conducted a review in Acute ischemic stroke. Intravenous thrombolysis (including tenecteplase and alteplase) was evaluated. Intravenous thrombolysis in acute ischemic stroke has evolved over the past 5 years, including greater use of tenecteplase, broader indications, and integration with endovascular thrombectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: